A multicenter Phase II study of Epirubicin (E) with low-dose Herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary results

被引：0
|
作者：
De Tursi, M.
Carella, C.
Ricevuto, E.
Marchetti, P.
Gennari, A.
Orlandini, C.
Frassoldati, A.
Conte, P.
Iacobelli, S.
机构：
[1] Univ G dAnnunzio, Dept Oncol & Neurosci, Chieti, Italy
[2] Univ Aquila, Dept Oncol, I-67100 Laquila, Italy
[3] Univ Pisa, Dept Oncol, I-56100 Pisa, Italy
[4] Univ Modena, Dept Oncol, I-41100 Modena, Italy
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：116 / 116
页数：1
相关论文
共 50 条
  • [41] Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
    Baselga, J
    Tripathy, D
    Mendelsohn, J
    Baughman, S
    Benz, CC
    Dantis, L
    Sklarin, NT
    Seidman, AD
    Hudis, CA
    Moore, J
    Rosen, PP
    Twaddell, T
    Henderson, IC
    Norton, L
    SEMINARS IN ONCOLOGY, 1999, 26 (04) : 78 - 83
  • [42] Phase II Study of Vinorelbine Plus Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer Pretreated With Anthracyclines and Taxanes
    Kwon, H.
    Oh, S. Y.
    Kim, S. H.
    Lee, S.
    Lee, J. H.
    Kim, H. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S353 - S353
  • [43] A phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer (MBC): Interim safety results
    Brufsky, A. M.
    Hoelzer, K. L.
    Keaton, M. R.
    Beck, J. T.
    Krill-Jackson, E.
    Wang, Y.
    Hu, S.
    Vaughn, L. G.
    Shonukan, O. O.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] Phase II Multicenter Study of Docetaxel and Bevacizumab (Bev) plus /- Trastuzumab as First-Line Treatment of Patients with Metastatic Breast Cancer (MBC)
    Schwartzberg, L. S.
    Hermann, R.
    Blakely, J.
    Richey, S. S.
    Tauer, K. W.
    Childs, B. H.
    CANCER RESEARCH, 2010, 70
  • [45] THE PRELIMINARY RESULTS OF PHASE II STUDY: NEOADJUVANT CHEMOTHERAPY AND LOW-DOSE RADIOTHERAPY FOR BREAST CANCER
    Nardone, L.
    De Santis, M. C.
    Terribile, D.
    Mantini, G.
    Mattiucci, G. C.
    Franceschini, G.
    Mule, A.
    Masetti, R.
    Valentini, V.
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S305 - S305
  • [46] A phase II study of weekly low-dose paclitaxel plus 24-hour infusion of cisplatin as first-line chemotherapy for metastatic breast cancer (MBC)
    Shen, Y.
    Hsu, C.
    Kuo, S.
    Lu, Y.
    Lin, C.
    Huang, C.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] Multicenter phase I/II study of efficacy, safety, and pharmacokinetics of vinorelbine and trastuzumab as first-line therapy for HER2-overexpressing metastatic breast cancer
    Aogi, Kenjiro
    Toi, Masakazu
    Iwata, Hiroji
    Ito, Yoshinori
    Sano, Muneaki
    Sato, Yasuyuki
    Saeki, Toshiaki
    Takashima, Shigemitsu
    ANNALS OF ONCOLOGY, 2006, 17 : 75 - 76
  • [48] Capecitabine (X) plus trastuzumab (H) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer (MBC): phase II trial results.
    Xu, L.
    Song, S.
    Zhu, J.
    Luo, R.
    Li, L.
    Jiao, S.
    Pan, H.
    Tao, M.
    Su, Y.
    Liu, D.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S102 - S102
  • [49] Capecitabine and trastuzumab: a phase II study in HER2-overexpressing metastatic breast cancer (MBC) patients pretreated with anthracyclines and/or taxanes
    Schaller, G
    Bangemann, N
    Gonsch, T
    Weber, J
    Kleine-Tebbe, A
    Conrad, B
    Klare, P
    Hindenburg, HJ
    Ruhmland, B
    Lakner, V
    Hinke, A
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S94 - S95
  • [50] Final results from a phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2-overexpressing metastatic breast cancer (MBC)
    Dickler, M.
    Franco, S.
    Stopeck, A.
    Ma, W.
    Nulsen, B.
    Lyandres, J.
    Melisko, M.
    Lahiri, S.
    Arbushites, M.
    Koehler, M.
    Rugo, H. S.
    CANCER RESEARCH, 2009, 69 (02) : 242S - 242S
12345